Cargando…
ALDH1A3‐mTOR axis as a therapeutic target for anticancer drug‐tolerant persister cells in gastric cancer
Tumors consist of heterogeneous cell populations that contain cancer cell subpopulations with anticancer drug‐resistant properties called “persister” cells. While this early‐phase drug tolerance is known to be related to the stem cell‐like characteristic of persister cells, how the stem cell‐related...
Autores principales: | Kawakami, Ryuhei, Mashima, Tetsuo, Kawata, Naomi, Kumagai, Koshi, Migita, Toshiro, Sano, Takeshi, Mizunuma, Nobuyuki, Yamaguchi, Kensei, Seimiya, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060474/ https://www.ncbi.nlm.nih.gov/pubmed/31960523 http://dx.doi.org/10.1111/cas.14316 |
Ejemplares similares
-
In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells
por: Mashima, Tetsuo, et al.
Publicado: (2019) -
Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo
por: Mashima, Tetsuo, et al.
Publicado: (2021) -
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016) -
mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer
por: Mashima, Tetsuo, et al.
Publicado: (2017) -
mTOR signaling: implications for cancer and anticancer therapy
por: Petroulakis, E, et al.
Publicado: (2006)